Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
JAK-STAT activation contributes to cytotoxic T cell–mediated basal cell death in human chronic lung allograft dysfunction
Aaditya Khatri, Jamie L. Todd, Fran L. Kelly, Andrew Nagler, Zhicheng Ji, Vaibhav Jain, Simon G. Gregory, Kent J. Weinhold, Scott M. Palmer
Aaditya Khatri, Jamie L. Todd, Fran L. Kelly, Andrew Nagler, Zhicheng Ji, Vaibhav Jain, Simon G. Gregory, Kent J. Weinhold, Scott M. Palmer
View: Text | PDF
Resource and Technical Advance Pulmonology Transplantation

JAK-STAT activation contributes to cytotoxic T cell–mediated basal cell death in human chronic lung allograft dysfunction

  • Text
  • PDF
Abstract

Chronic lung allograft dysfunction (CLAD) is the leading cause of death in lung transplant recipients. CLAD is characterized clinically by a persistent decline in pulmonary function and histologically by the development of airway-centered fibrosis known as bronchiolitis obliterans. There are no approved therapies to treat CLAD, and the mechanisms underlying its development remain poorly understood. We performed single-cell RNA-Seq and spatial transcriptomic analysis of explanted tissues from human lung recipients with CLAD, and we performed independent validation studies to identify an important role of Janus kinase–signal transducer and activator of transcription (JAK-STAT) signaling in airway epithelial cells that contributes to airway-specific alloimmune injury. Specifically, we established that activation of JAK-STAT signaling leads to upregulation of major histocompatibility complex 1 (MHC-I) in airway basal cells, an important airway epithelial progenitor population, which leads to cytotoxic T cell–mediated basal cell death. This study provides mechanistic insight into the cell-to-cell interactions driving airway-centric alloimmune injury in CLAD, suggesting a potentially novel therapeutic strategy for CLAD prevention or treatment.

Authors

Aaditya Khatri, Jamie L. Todd, Fran L. Kelly, Andrew Nagler, Zhicheng Ji, Vaibhav Jain, Simon G. Gregory, Kent J. Weinhold, Scott M. Palmer

×

Figure 3

Activation of JAK-STAT pathway in CLAD basal cells mediates overexpression of MHC-I.

Options: View larger image (or click on image) Download as PowerPoint
Activation of JAK-STAT pathway in CLAD basal cells mediates overexpressi...
(A) Schematic showing JAK-STAT activation leads to nuclear localization of STAT1 where it binds to IFN-sensitive response element (ISRE) leading to upregulation of IFN stimulating genes (ISGs), including MHC-I–expressing genes (B2M, HLA-A, HLA-B, HLA-C). (B) Immunofluorescence shows increased nuclear localization for STAT1 (red) in CLAD compared with control basal cells (KRT5+, green) (n = 6 CLAD cases and 6 controls). DAPI, blue. Scale bar: 10 μm. (C) Quantification of nuclear localization of STAT1 in CLAD compared with control basal cells. (D) Immunoblotting for phospho-STAT1, STAT1, B2M, and GAPD in primary basal cells isolated from donor controls shows activation of JAK1-STAT1 signaling and upregulation of MHC-I following stimulation with IFNA1 (100 ng/μL). This response is partially rescued with cotreatment with the JAK1 inhibitor, brepocitinib (0.5 μM). (E and F) Quantification showing a significant decrease in IFN-mediated activation of JAK-STAT pathway in cells treated with a JAK1 inhibitor (n = 3 biological replicates). Statistical analysis for immunofluorescence experiments was performed using the unpaired parametric t test, while analysis for Western blots was performed using the 1-way ANOVA (P < 0.05) with post hoc Tukey test. Data are shown as mean ± SEM. *P < 0.05, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts